Skip to main content

Table 7 Relation between genotypes and clinicopathological data among HCC patients

From: Association between miR-196a2 polymorphism and the development of hepatocellular carcinoma in the Egyptian population

Studied variableGenotypeKruskal–Wallis testP value
CC
N = 21
TC
N = 42
TT
N = 17
AST (U/L)
 Min-max12.0–302.021.0-540.014.00-258.000.380.82
X ± SD83.96 ± 70.88158.04 ± 269.9990.56 ± 78.90
 Median67.5093.0066.00
ALT (U/L)
 Min-max11.0–292.0012.0–379.011.0–205.01.100.57
X ± SD80.14 ± 61.6883.57 ± 83.4567.82 ± 49.62
 Median64.00000059.0053.0
ALB (g/dL)
 Min-max2.0–4.02.0–4.02.0–4.01.250.53
X ± SD2.73 ± .702.54 ± .582.61 ± .67
 Median3.03.002.0
BT (mg/dL)
 Min-max1.0–16.01.0–20.01.0–9.00.050.97
X ± SD4.03 ± 3.963.66 ± 3.543.36 ± 2.43
Median2.03.003.00
BD (mg/dL)
 Min-max1.0–16.01.0–15.001.0–8.00.940.62
X ± SD3.58 ± 4.462.55 ± 2.923.03 ± 2.56
 Median1.001.02.0
AFP (ng/mL)
 Min-max12-520011-20,9496-19,0073.350.18
X ± SD1586.48 ± 1513.681801.07 ± 4254.212052.71 ± 4561.92
 Median615.00420.00680.00
Focal lesion
 Min-max1.50–9.001.50–8.002.00–11.001.50.22
X ± SD4.81 ± 2.103.99 ± 1.724.75 ± 2.07
 Median5.004.04.50
PT. conc
 Min-max19-9620-10229–890.730.69
X ± SD56.26 ± 18.6659.40 ± 16.5458.43 ± 16.53
 Median55.0063.0057.00
PT.INR
 Min-max1.03–2.71.95–3.591.08–2.400.610.73
X ± SD1.54 ± .451.45 ± .451.47 ± .37
 Median1.41501.33001.45